1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Competitive Grants Program is sponsored by Pfizer. Pfizer supports independent initiatives, including research, to improve patient outcomes in areas of unmet medical need aligned with Pfizer's medical and/or scientific strategies. Specific opportunities are announced via Request for Proposals (RFPs).
While no current RFP explicitly mentions adipose organoid microphysiological systems, research in this area could align with broader biomedical and disease-focused interests.
Get alerted about grants like this
Save a search for “Pfizer” or related topics and get emailed when new opportunities appear.
Search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Competitive Grants Program | Pfizer Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.
The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Efforts to Improve Quality of Migraine Care Release Date: March 4, 2026 Partner: The Japanese Headache Society Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Internal Medicine Japan June 15, 2026 Improving Health Outcomes in Patients with ATTR-CM Through the Development of a Shared Decision-Making Tool (Decision Aid) Release Date: March 10, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Rare Disease USA June 3, 2026 Optimizing Adult Vaccination Ecosystem in India Release Date: March 16, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Vaccines India May 14, 2026 Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic Dermatitis Release Date: March 17, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA May 13, 2026 Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Release Date: March 18, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Oncology Spain May 22, 2026 Diagnosis and Treatment of Cancer Cachexia Release Date: March 24, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology All May 14, 2026 Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic Diseases Release Date: March 26, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Inflammation & Immunology USA May 21, 2026 B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM) Release Date: March 27, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology USA May 18, 2026 Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia Areata Release Date: March 30, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Inflammation & Immunology USA May 25, 2026 2026 Hemophilia Fellowship – United States Release Date: April 1, 2026 Review Process: Expert Review Panel View RFP (PDF) Fellowship Rare Disease All May 28, 2026 Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Pneumococcal Disease Prevention Release Date: April 11, 2012 Review Process: View RFP (PDF) Release Date: May 8, 2012 Review Process: View RFP (PDF) Release Date: June 28, 2012 Review Process: View RFP (PDF) Pharmacy Pneumococcal Disease Prevention Release Date: June 28, 2012 Review Process: View RFP (PDF) Release Date: July 2, 2012 Review Process: View RFP (PDF) Non-Small Cell Lung Cancer Release Date: July 10, 2012 Review Process: View RFP (PDF) Cardiovascular Risk in Rheumatoid Arthritis Release Date: July 25, 2012 Review Process: View RFP (PDF) Release Date: July 26, 2012 Review Process: View RFP (PDF) Adult Pneumococcal Disease Prevention Release Date: August 29, 2012 Review Process: View RFP (PDF) Prevention of Stroke in Women Release Date: September 13, 2012 Review Process: View RFP (PDF) Oncology Educational Needs Assessments Release Date: October 22, 2012 Review Process: View RFP (PDF) Release Date: November 1, 2012 Review Process: View RFP (PDF)
Based on current listing details, eligibility includes: Organizations are invited to submit an application addressing specific gaps in research, practice, or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Varies Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is rolling deadlines or periodic funding windows. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Surveillance of Pneumococcal Disease Serotype Distribution in Pediatric and Adult Pneumococcal Disease in Türkiye is a grant from Pfizer that funds STEM education research. The supported studies should focus on clinically confirmed pneumococcal infections, determining the serotype-specific prevalence and serotype distribution as well as antimicrobial resistance patterns in pneumococcal isolates. By also leveraging passive data sources, such as hospital records and laboratory reports, this initiative is expected to provide epidemiological insights. Eligible applicants include healthcare organizations in Turkey. The application deadline is 2026-05-04.
Pfizer Global Medical Grants: Sickle Cell Disease Research is a grant from Pfizer Inc. that funds innovative programs addressing healthcare access, advocacy, and data collection for people living with sickle cell disease (SCD). The Sickle Cell Advocacy and Leadership Empowerment (SCALE) Grants program supports three categories: Assessment and Analysis, Policy and Advocacy, and Data Collection/Surveillance. Pfizer awards a total of $150,000 across 5–7 pilot accelerator projects lasting 12–18 months, with indirect costs capped at 28%. Eligible applicants are organizations with capacity to measure program outcomes and connect work to policy goals affecting the SCD community. Applications for the 2025 cycle were due October 15, 2025; applicants should monitor Pfizer's grant portal for future cycles.